When a previously healthy young person dies suddenly and a full autopsy finds nothing, families are often left with a devastating void: no cause, no explanation, and no way of knowing whether other relatives carry the same hidden risk. A new systematic review and meta-analysis published in the International Journal of Legal Medicine offers the most rigorous accounting to date of what postmortem genetic testing, known as molecular autopsy, can actually deliver in these cases, and the results are both sobering and quietly transformative. Pooling data from 44 core studies encompassing 4,041 index cases, an international team led by Raghvendra Singh of Era’s Lucknow Medical College and Hospital found that when variant interpretations are corrected to modern American College of Medical Genetics and Genomics (ACMG) standards, the pooled diagnostic yield of molecular autopsy is approximately 13 percent, a modest figure that nevertheless translates into thousands of families who could receive a concrete genetic explanation for a loved one’s unexplained death.
The study, registered in PROSPERO (CRD420251082728) and conducted according to PRISMA guidelines, tackled a problem that has long plagued the field: the wildly varying estimates of diagnostic yield reported across individual molecular autopsy studies, which have ranged from single digits in early candidate-gene screens to more than 30 percent in some whole-exome sequencing cohorts. The authors recognized that much of this variability was an artifact of inconsistent variant classification. Older studies frequently counted variants of uncertain significance, or VUS, as positive findings, inflating apparent yields, while others applied gene-disease validity standards that would not survive contemporary scrutiny. By correcting all reported yields to ACMG-compatible classification, in which only pathogenic and likely pathogenic variants in genes with established disease associations count as diagnostic, the researchers produced a standardized figure that clinicians and forensic investigators can actually use when deciding whether to invest in postmortem genetic testing.
Beyond the headline yield, the meta-analysis revealed a clear relationship between sequencing strategy and diagnostic success. Broader sequencing approaches, such as whole-exome and large multi-gene panels, showed modestly but significantly higher yields than restricted candidate-gene panels, with an odds ratio of 1.36 (95% confidence interval 1.09–1.70; p = 0.006). This finding confirms quantitatively what many in the field have suspected: casting a wider genomic net catches more causative variants. But the wider net comes at a cost. Broader sequencing also generated a substantially greater burden of VUS, variants whose clinical significance cannot be determined from available evidence. These uncertain findings pose a genuine dilemma in the postmortem setting, where the deceased cannot be examined clinically and phenotype information is limited to circumstantial accounts of the death itself.
The analysis also stratified results by age, uncovering a striking pattern. Young adult and adult cohorts showed the highest pooled diagnostic yields, consistent with the notion that in these age groups, deaths are more likely to be driven by single, highly penetrant variants in well-characterized arrhythmia and cardiomyopathy genes. In contrast, infant and pediatric cohorts displayed a broader multisystem genomic architecture, implicating genes involved in diverse developmental and metabolic pathways rather than a narrow set of cardiac ion channel genes. These younger cohorts also carried higher VUS burdens, reflecting both the wider genetic landscape involved in early-life sudden death and the relative paucity of validated disease genes for many pediatric conditions. This has practical implications: laboratories interpreting molecular autopsy results in infants and children should expect more ambiguous findings and may need to consider syndromic and multisystem diagnoses that would not arise in adult cases.
Across all cohorts, a recurring cast of culprit genes emerged. RYR2, which encodes the cardiac ryanodine receptor governing calcium release from the sarcoplasmic reticulum, was among the most frequently implicated, consistent with its central role in catecholaminergic polymorphic ventricular tachycardia, a condition that causes sudden death during exertion or emotional stress in structurally normal hearts. SCN5A, encoding the cardiac sodium channel responsible for the rapid upstroke of the cardiac action potential, appeared repeatedly, as did KCNQ1 and KCNH2, the potassium channel genes underlying the most common forms of long QT syndrome. Structural heart genes also featured prominently: TTN, encoding the giant sarcomeric protein titin, and MYBPC3, encoding myosin-binding protein C, both well-established causes of inherited cardiomyopathy. Together, these genes represent the biological backbone of unexplained sudden death, spanning the electrical and mechanical machinery of the heart.
Perhaps the most clinically consequential finding of the review concerns what happens after a positive molecular autopsy result. Thirty-five of the included studies provided family-translation data, documenting what occurred when genetic findings were communicated back to surviving relatives. The results paint a compelling picture of molecular autopsy as not merely a diagnostic tool for the deceased, but as the entry point into a cascade of preventive medicine for the living. Genotype-positive relatives, meaning family members who carry the same variant identified in the decedent, were frequently identified through cascade screening, as were phenotype-positive relatives who showed clinical evidence of disease on cardiac evaluation even without the family variant. Formal segregation analysis, in which the variant’s co-transmission with disease is tracked through a pedigree, was commonly performed to strengthen or refute pathogenicity assignments. Critically, clinically actionable interventions were frequently reported: beta-blockers, implantable cardioverter-defibrillators, lifestyle modifications, and targeted pharmacotherapy that can prevent the same sudden death from claiming another member of the family.
The concept of “family translation” is central to the authors’ argument about the true value of molecular autopsy. A 13 percent yield might seem underwhelming if viewed purely as a diagnostic statistic for individual deaths. But when reframed as a population-level intervention, the calculus changes dramatically. Each diagnostic result in a decedent potentially triggers the identification of multiple at-risk relatives, many of whom are asymptomatic but carry a life-threatening, treatable condition. In inherited arrhythmia syndromes such as long QT syndrome, preventive treatment can reduce sudden death risk dramatically, meaning that a single molecular autopsy result may avert multiple premature deaths across a family tree. The authors argue that contemporary ACMG-compatible molecular autopsy should be understood not as a forensic curiosity but as a cornerstone of family-based preventive genomic medicine.
The technical rigor of the review also sheds light on the maturation of the field itself. Early molecular autopsy efforts in the late 1990s and 2000s relied on Sanger sequencing of a handful of candidate genes, most famously the three major long QT syndrome genes, producing yields that reflected the narrowness of the query rather than the full genetic substrate of sudden death. The advent of next-generation sequencing enabled panels of dozens to hundreds of genes, and subsequently whole-exome and whole-genome approaches that could interrogate the entire coding sequence. Each technological generation brought higher raw yields but also greater complexity in interpretation, as the number of rare variants of unknown significance grew in parallel with the number of genes examined. The ACMG framework, with its five-tier classification system from benign to pathogenic and its emphasis on gene-disease validity, emerged as the necessary corrective to this interpretive chaos. The new meta-analysis demonstrates that applying this framework uniformly across the published literature produces a diagnostic yield estimate that is far more trustworthy than the scattered figures that preceded it.
The findings carry immediate implications for forensic practice and health policy. In many jurisdictions, molecular autopsy is not routinely performed or is not covered by public health systems, and medical examiners often lack access to genetic counseling services needed to translate results to families. The demonstration that broad sequencing outperforms restricted panels, even after accounting for the VUS burden, argues for investment in comprehensive postmortem genomic testing rather than piecemeal candidate-gene approaches. At the same time, the persistent VUS problem underscores the need for ongoing variant reclassification efforts, as variants once deemed uncertain may be reclassified as knowledge accumulates, converting non-diagnostic results into actionable findings years after the original test. The authors also highlight the importance of structured pathways connecting forensic genetics laboratories with clinical cardiology and genetics services, so that a positive postmortem finding reliably triggers cascade screening rather than languishing in a forensic report.
The review is not without limitations inherent to its design. The substantial heterogeneity observed across studies, acknowledged by the authors, reflects genuine differences in cohort composition, sequencing technology, reporting standards, and geographical ancestry of the populations studied. Publication bias likely inflates yield estimates, as studies finding nothing reportable are less likely to be published. And because the analysis relies on previously published data, the quality of family-translation reporting varied considerably, making it difficult to quantify precisely how often molecular autopsy results lead to clinically meaningful interventions in relatives. Nonetheless, by standardizing variant classification across 4,041 cases, the study provides the most reliable benchmark yet available for what families and clinicians can realistically expect from postmortem genetic testing.
As molecular autopsy moves from an emerging experimental tool to an established component of sudden death investigation, this meta-analysis arrives at a pivotal moment. Its central message is nuanced but clear: molecular autopsy delivers a modest yield when measured against modern classification standards, but its true power lies in what happens downstream. For the roughly one in eight families who receive a genetic explanation, the result converts an inexplicable tragedy into actionable medical knowledge. For the field as a whole, the study establishes a rigorous, ACMG-corrected baseline against which future improvements in sequencing technology, variant interpretation, and family-centered care can be measured.
Subject of Research: Molecular autopsy and postmortem genetic testing in unexplained sudden death, including ACMG-corrected diagnostic yield, genomic architecture, and family translation outcomes.
Subject of Research: Medicine
Article Title: Molecular autopsy in unexplained sudden death: a systematic review and meta-analysis of ACMG-corrected diagnostic yield, genomic architecture, and family translation
Article References: Singh, R., Garg, R. K., Singh, H., & Verma, A. K. (2026). Molecular autopsy in unexplained sudden death: a systematic review and meta-analysis of ACMG-corrected diagnostic yield, genomic architecture, and family translation. International Journal of Legal Medicine. https://doi.org/10.1007/s00414-026-03935-6
Image Credits: AI Generated
DOI: 10.1007/s00414-026-03935-6
Keywords: Molecular autopsy, Sudden unexplained death, Postmortem genetic testing, Inherited arrhythmia syndromes, ACMG variant classification, Cascade screening, Diagnostic yield, RYR2, SCN5A, Next-generation sequencing, Sudden cardiac death, Family-based preventive genomic medicine
Cite Scienmag News
APA
MLA
Chicago
Juliet Wilcox. (September 6, 2026). Genetic autopsy findings in unexplained sudden cardiac deaths reviewed. Scienmag. https://scienmag.com/genetic-autopsy-findings-in-unexplained-sudden-cardiac-deaths-reviewed/
Juliet Wilcox. “Genetic autopsy findings in unexplained sudden cardiac deaths reviewed.” Scienmag, 6 September 2026, https://scienmag.com/genetic-autopsy-findings-in-unexplained-sudden-cardiac-deaths-reviewed/. Accessed 6 September 2026.
Juliet Wilcox. “Genetic autopsy findings in unexplained sudden cardiac deaths reviewed.” Scienmag. September 6, 2026. https://scienmag.com/genetic-autopsy-findings-in-unexplained-sudden-cardiac-deaths-reviewed/
Copy citation
Download RIS
Tags: ACMG standards in genetic interpretationadvances in postAmerican College of Medical Genetics guidelines in autopsydiagnostic yield of molecular autopsyfamilial risk assessmentfamilial risk assessment in sudden cardiac deathgenetic autopsyGenetic autopsy in sudden cardiac deathgenetic cause of sudden deathgenetic risk factors for unexplained sudden deathimpact of genetic testing on families after cardiac deathinternational meta-analysis of genetic findings in cardiac deathlegal medicine and genetic testingmolecular autopsymolecular autopsy diagnostic yieldpostmortem genetic analysis for young sudden deathpostmortem genetic diagnosispostmortem genetic testingstandardization of genetic interpretation in autopsiessudden cardiac deathsystematic review and meta-analysissystematic review of molecular autopsy studiesunexplained cardiac deathunexplained cardiac death genetic testing
